Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis
K. Rajender Reddy, Marc Bourlière, Mark Sulkowski, Masao Omata, Stefan Zeuzem, Jordan J. Feld, Eric Lawitz, Patrick Marcellin, Tania M. Welzel, Robert Hyland, Xiao Ding, Jenny Yang, Steven Knox, Phillip Pang, Hadas Dvory‐Sobol, G. Mani Subramanian, William Symonds, John G. McHutchison, Alessandra Mangia, Edward Gane, Masashi Mizokami, Stanislas Pol, Nezam Afdhal – 4 April 2015 – Patients with hepatitis C virus (HCV) infection and cirrhosis are underrepresented in clinical trials of interferon‐free regimens of direct‐acting antiviral agents, making it difficult to optimize therapy.